Objective: To elicit quality of life of chronic kidney disease (CKD) patients with routine hemodialysis receiving erythropoietin from clinical and humanistic outcome, to analysis characteristic factors to Hb, fatique and the quality of life (QOL) of CKD patients with routine hemodialysis, and to explore the change in QOL over one month for patients managed in the hospitals. Methods: A prospective study was conducted among adult CKD patients in Haji Adam Malik Hospital Medan. QOL was measured using kidney disease quality of life – short form (KDQOL–SFTM) questionnaire and FACIT fatigue scale questionnaire. CKD patients. Patients were asked to complete the KDQOL–SFTM questionnaire and FACIT fatigue scale questionnaire two times in one month range. Results: Average rate of haemoglobin was increased after one month anemia treatment using erythropoietin 8.68: 8.82. Average rate of FACIT was increased after one month anemia treatment using erythropoietin 43.98: 44.81. Average rate of KDQOL was increased after one month anemia treatment using erythropoietin 76.83: 77.94. Conclusion: Erythropoietin can improve QOL of CKD patients with routine hemodialysis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.